Pathogenesis of Selective Insulin Resistance in Isolated Hepatocytes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The development of insulin resistance (IR) in the liver is a key pathophysiologic event in the development of type 2 diabetes. Although insulin loses its ability to suppress glucose production, it largely retains its capacity to drive lipogenesis. This selective IR results in the characteristic hyperglycemia and dyslipidemia of type 2 diabetes. The delineation of two branched pathways of insulin receptor (InsR) signaling to glucose versus triglyceride production, one through FoxO and the other through SREBP-1c, provides a mechanism to account for this pathophysiological abnormality. We tested the complementary hypothesis that selective IR arises due to different intrinsic sensitivities of glucose production versus de novo lipogenesis to insulin as a result of cell-autonomous down-regulation of InsR number in response to chronic hyperinsulinemia. We demonstrate in mouse primary hepatocytes that chronic hyperinsulinemia abrogates insulin's inhibition of glucose production, but not its stimulation of de novo lipogenesis. Using a competitive inhibitor of InsR, we show that there is a 4-fold difference between levels of InsR inhibition required to cause resistance of glucose production versus lipogenesis to the actions of insulin. Our data support a parsimonious model in which differential InsR activation underlies the selective IR of glucose production relative to lipogenesis, but both processes require signaling through Akt1/2. Background: The liver produces both excessive glucose and lipids in type 2 diabetes. Results: Glucose production is more vulnerable to insulin receptor (InsR) impairment ex vivo than is lipogenesis. Conclusion: Selective insulin resistance arises due to inherent, cell-autonomous differences in the insulin responsiveness of glucose versus lipid metabolism. Significance: InsR itself may represent a locus of treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“CHI that arises as an early manifestation of insulin resistance may trigger partial down-regulation of InsR in liver (12, 13), leading to a situation in which suppression of HGP is achieved at the price of stimulating DNL.”
BackgroundInsulin Resistance and Hyperinsulinemia
Shanik, M. H., Xu, Y., Škrha, J., Dankner, R., Zick, Y., & Roth, J. (2008) · Diabetes Care · doi:10.2337/dc08-s264 · Cited by 791
Li, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733 · cited 2×
“Although previous studies investigating expression of lipogenic genes in primary hepatocytes suggested this possibility, these studies did not measure DNL directly (10, 32, 33, 57).”
BackgroundNakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112876 · Cited by 652
Self-citationHormonal regulation of hepatic glucose production in health and disease
Lin, H. V., & Accili, D. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.003 · Cited by 429
Self-citationCaro, J. F., Sinha, M. K., Raju, S. M., Ittoop, O., Pories, W. J., Flickinger, E. G., Meelheim, D., & Dohm, G. L. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112958 · Cited by 341
Freidenberg, G. R., Henry, R. R., Klein, H. H., Reichart, D. R., & Olefsky, J. M. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112789 · Cited by 234
Caro, J. F., Ittoop, O., Pories, W. J., Meelheim, D., Flickinger, E. G., Thomas, F., Jenquin, M., Silverman, J. F., Khazanie, P. G., & Sinha, M. K. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112558 · Cited by 215 · cited 4×
“Indeed, insulin binding to human liver plasma membranes was decreased by about 50%, similar to the extent of down-regulation in our model of CHI, in non-diabetic and diabetic obese patients as compared with non-obese controls (8, 44).”
BackgroundResultInfluential(2008) · doi:10.1016/j.cmet.2008.06.010 · Cited by 67 · cited 1×
“Although the pathophysiology of selective IR remains unclear, it is generally acknowledged that the pathways to insulin regulation of glucose versus triglyceride production diverge downstream of Akt (6).”
BackgroundSelf-citation
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International · doi:10.1111/liv.13185 · Cited by 171
Cuthbertson, D. J., Shojaee-Moradie, F., Sprung, V. S., Jones, H., Pugh, C. J. A., Richardson, P., Kemp, G. J., Barrett, M., Jackson, N. C., Thomas, E. L., et al. (2016) · Clinical Science · doi:10.1042/cs20150447 · Cited by 138
Metadata
- Authors
- Cook, J. R., Langlet, F., Kido, Y., & Accili, D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 290
- Issue
- 22
- Pages
- 13972-13980
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2074913439
- Cited by
- 83
- References
- 10
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenesis of Selective Insulin Resistance in Isolated Hepatocytes. https://app.cochat.ai/papers/10.1074/jbc.m115.638197
- The paper
- Cook, J. R., Langlet, F., Kido, Y., & Accili, D. (2015). Pathogenesis of Selective Insulin Resistance in Isolated Hepatocytes. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m115.638197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.